Cannabis Science Inc., a U.S. company specializing in cannabis formulation-based drug development, issued CBN patent and R&D guidance for the 2nd quarter of 2014.

 

To support its existing CBN patent, the company delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer’s disease. 

 

Earlier this year the company raised funds to facilitate Cannabis Science’s R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the company’s new product to address neurobehavioral disorders. 

 

“Cannabis Science has made solid progress so far this year. I am proud to be a part of this team and I am very positive about our future,” stated Robert Kane, CFO of Cannabis Science.

 

In conjunction, the company is discussing the initiation of additional clinical studies using pharmaceutical grade cannabis in proprietary, topical and orally administered applications to various skin conditions including skin cancer work to be conducted in several geographic areas in collaboration with multiple potential partners. 

 

The company is finalizing discussions with further research groups to ensure timely completion of the planned development. Following the completion of the toxicity and the pre-clinical efficacy studies the company plans to proceed into clinical studies during the next year. Work has also been initiated on the formulations and negotiations are underway to establish several commercial partnerships in this area.

 

Date; May 22, 2014

Source: Cannabis Science